Strategic Fundraising Sofinnova Investments is a healthcare-focused investment firm with a substantial $4.6B in assets under management and committed capital as of March 31, 2026, signaling strong capital availability for portfolio support, follow-on rounds, and potential co-investment opportunities.

Active Portfolio Expansion Recent high-profile investments in City Therapeutics, Expedition Therapeutics, and One Biosciences indicate Sofinnova’s appetite for novel biotech ventures at multiple stages, presenting opportunities for collaboration, syndicated funding, and strategic advisory roles.

Global Footprint With a track record spanning the U.S. and Europe and a long-established presence since 1976, Sofinnova offers cross-border expertise, regulatory navigation support, and potential market access benefits for companies aiming to scale internationally.

Clinical and Regulatory Focus Sofinnova emphasizes funding products that impact patients and supports navigating drug development and regulatory processes, making them a potential partner for companies seeking grant-style or milestone-driven financing aligned with clinical milestones.

Revenue and Scale Signals Reported revenue range of $50M–$100M suggests Sofinnova operates at a sizable scale, which may indicate readiness for larger co-investments, strategic exits, or partnerships for mature portfolio companies seeking growth equity or M&A alignment.